Zlotta AR - Search Results

1

Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review.

Perlis N, Zlotta AR, Beyene J, Finelli A, Fleshner NE, Kulkarni GS. Perlis N, et al. Among authors: zlotta ar. Eur Urol. 2013 Sep;64(3):421-30. doi: 10.1016/j.eururo.2013.06.009. Epub 2013 Jun 19. Eur Urol. 2013. PMID: 23830475 Review.

2

Prostate cancer prevention: past, present, and future.

Fleshner N, Zlotta AR. Fleshner N, et al. Among authors: zlotta ar. Cancer. 2007 Nov 1;110(9):1889-99. doi: 10.1002/cncr.23009. Cancer. 2007. PMID: 17893870 Free article. Review.

3

When and how to treat superficial and muscle-invasive bladder cancer.

Zlotta AR. Zlotta AR. Eur Urol. 2007 Dec;52(6):1554-7. doi: 10.1016/j.eururo.2007.09.033. Epub 2007 Sep 25. Eur Urol. 2007. PMID: 17904728 No abstract available.

4

Pharmacotherapy for prostate cancer: the role of hormonal treatment.

Shahani R, Fleshner NE, Zlotta AR. Shahani R, et al. Among authors: zlotta ar. Discov Med. 2007 Aug;7(39):118-24. Discov Med. 2007. PMID: 18093474 Free article.

5

Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection.

Al-Ghamdi AM, Lockwood G, Toi A, Kulkarni GS, Evans A, Finelli A, Zlotta AR, Fleshner N. Al-Ghamdi AM, et al. Among authors: zlotta ar. J Urol. 2008 Apr;179(4):1332-4. doi: 10.1016/j.juro.2007.11.067. Epub 2008 Mar 4. J Urol. 2008. PMID: 18289588

6

The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.

Musquera M, Fleshner NE, Finelli A, Zlotta AR. Musquera M, et al. Among authors: zlotta ar. Expert Rev Anticancer Ther. 2008 Jul;8(7):1073-9. doi: 10.1586/14737140.8.7.1073. Expert Rev Anticancer Ther. 2008. PMID: 18588452 Clinical Trial.

7

Thirty-five years of noninvasive bladder carcinoma: a plea for the use of papillary intraurothelial neoplasia as new terminology.

Van der Kwast TH, Zlotta AR, Fleshner N, Jewett M, Lopez-Beltran A, Montironi R. Van der Kwast TH, et al. Among authors: zlotta ar. Anal Quant Cytol Histol. 2008 Dec;30(6):309-15. Anal Quant Cytol Histol. 2008. PMID: 19160695

8

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.

van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. van Rhijn BW, et al. Among authors: zlotta ar. Eur Urol. 2009 Sep;56(3):430-42. doi: 10.1016/j.eururo.2009.06.028. Epub 2009 Jun 26. Eur Urol. 2009. PMID: 19576682 Review.

9

The fate of an unsatisfactory urine cytology test among patients with urothelial carcinoma.

Ordon M, Boerner S, Zlotta AR, Jewett MA, Fleshner N. Ordon M, et al. Among authors: zlotta ar. BJU Int. 2009 Dec;104(11):1641-5. doi: 10.1111/j.1464-410X.2009.08650.x. Epub 2009 Jul 2. BJU Int. 2009. PMID: 19583723

10

An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.

Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, Zlotta A. Kulkarni GS, et al. Eur Urol. 2010 Jan;57(1):60-70. doi: 10.1016/j.eururo.2009.08.024. Epub 2009 Sep 1. Eur Urol. 2010. PMID: 19740595 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters